Open AccessAntimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide
Author(s) -
Hélio S. Sader,
Leonard R Duncan,
S J Ryan Arends,
Cecília G Carvalhaes,
Mariana Castanheira
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01433-20
Subject(s) - stenotrophomonas maltophilia , aztreonam , liter , microbiology and biotechnology , antimicrobial , trimethoprim , ceftazidime/avibactam , colistin , medicine , biology , antibiotics , pseudomonas aeruginosa , bacteria , antibiotic resistance , ceftazidime , imipenem , genetics
Aztreonam-avibactam was tested against 1,839 Stenotrophomonas maltophilia isolates collected worldwide and demonstrated potent activity against isolates from all geographic regions and infection types (overall MIC 50/90 , 4/4 mg/liter; 97.8% inhibited at ≤8 mg/liter). Trimethoprim-sulfamethoxazole (TMP-SMX) (MIC 50/90 , ≤0.5/1 mg/liter; 95.4% susceptible) and minocycline (MIC 50/90 , 0.5/2 mg/liter; 99.5% susceptible) were also very active. Aztreonam-avibactam inhibited 84.7% of non-TMP-SMX-susceptible isolates at ≤8 mg/liter. Aztreonam-avibactam may represent a valuable option for the treatment of S. maltophilia infections, addressing a major unmet medical need.